Novel medications, including GLP-1 receptor agonists (GLP-1 RA), are becoming a cornerstone of obesity management of metabolic disease given demonstrated improvements in glycemia, adiposity, and cardiovascular outcomes (5). The gene discussed is GLP1R; the disease is Other metabolic disease.